ALZN
A little stock surgery
Alzamend Neuro just got shareholder approval to perform a reverse stock split on its common shares, with the board now able to pick a ratio anywhere from 1-for-2 to 1-for-10. Translation: the company can shrink the share count and boost the share price, at least cosmetically.
Why investors should care
Reverse splits are one of those corporate moves that sound dramatic because, well, they usually are. They’re often used when a stock has been hanging out in penny-stock territory and needs a quick lift to stay compliant with exchange rules. That can buy time, but it doesn’t solve the harder stuff like clinical progress, financing needs, or actual revenue generation.
The fine print matters
The board has until April 16, 2027 to decide the exact ratio and timing. So this isn’t an immediate action, but it does give management a pretty wide tool kit if the share price keeps wobbling.
For investors, the big question is whether this is the first step in a stabilizing plan or just the financial equivalent of putting tape on a leaky pipe. Either way, it’s a sign the company is still focused on keeping its Nasdaq footing.
Big picture: reverse splits can be useful, but they’re usually a headline about survival mode, not a victory lap.